Koyfin Home > Directory > Health Care > Apellis Pharmaceuticals Inc > Long-Term Debt

Apellis Pharmaceuticals Inc Long-Term Debt Chart (APLS)

Apellis Pharmaceuticals Inc annual/quarterly Long-Term Debt from 2017 to 2018.
  • Apellis Pharmaceuticals Inc Long-Term Debt for the quarter ending December 12, 2018 was $25m a -4.88% decrease of -1m year over year
  • Apellis Pharmaceuticals Inc Long-Term Debt for the last 12 months ending December 12, 2018 was $25m a -4.88% decrease of -1m year over year
  • Apellis Pharmaceuticals Inc Annual Long-Term Debt for 2018 was $25m a -3.99% decrease of -1m from 2017
  • Apellis Pharmaceuticals Inc Annual Long-Term Debt for 2017 was $26m
Other Cash Flow Metrics:
  • Apellis Pharmaceuticals Inc Cash Flow from Operations for the quarter ending December 12, 2018 was $-44m a 48.43% decrease of -22m year over year
  • Apellis Pharmaceuticals Inc Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-39m a 62.21% decrease of -24m year over year
View Chart On Koyfin

Quarterly APLS Long-Term Debt Data

12/2018$25m
09/2018$27m
06/2018$27m
03/2018$27m
12/2017$26m

Annual APLS Long-Term Debt Data

2018$25m
2017$26m